Abbreviations: ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; siRNA, small interfering RNA; FBS, fetal bovine serum; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MEM, Minimal essential medium; NEAA, non-essential amino acids; BrdU, bromodeoxyuridine. MEK 1 and 2 are the only upstream molecules that are able to activate ERK 1 and 2.
Extracellular signal-regulated kinase (ERK) 1 and 2 are activated through the Ras-Raf-Mitogen-activated kinase (MAPK)/ERK kinase (MEK) pathway and play fundamental roles in a variety of pathophysiological conditions, such as embryonic development, inflammation, tumor growth, and angiogenesis [1, 2] . In particular, their important roles in regulating tumor cell proliferation and migration encouraged us to target these kinases as a potent therapeutic strategy for cancer patients [2] [3] [4] . MEK 1 and 2 are the only upstream molecules that are able to activate ERK 1 and 2.
Thus, specific inhibition of MEK achieves specific and efficient inactivation of ERK [3, 4] . In human cancer cells, ERK activity is frequently elevated than in normal adjacent cells [5] . It has been shown that MEK inhibitors potently blocked the tumor progression in xenografted animal models [6, 7] . However, MEK inhibitors did not affect human tumors in clinical trials [8, 9] .
To address the question of how human tumor cells evade the inhibitory action of MEK inhibition at a cellular level, we examined the effects of chronic exposure to PD98059 on human tumor cells. We show here for the first time that the chronic exposure of tumor cells to a MEK inhibitor upregulated the expression of ERK 2, which was involved in the decreased sensitivity of their proliferation to MEK inhibitor-treatment. cells were cultured in MEM supplemented with NEAA and 10% FBS, and DU145 cells were cultured in Ham's F-12 medium supplemented with 10% FBS. For the chronic exposure of cells to PD98059, cells were cultured in the presence of 50 M PD98059 for more than 4 weeks. To remove the effect of chronic exposure to PD98059, cells were further cultured without PD98059 for 2 weeks. The culture medium was changed to fresh medium every 3 days. As described below, these cells were examined biologically and biochemically in the presence or absence of PD98059 (the short-period treatment). To avoid confusion between chronic exposure and the short-period treatment with PD98059, unexposed parental cells were denoted ACHN (pa) or DU145 (pa) cells, cells chronically exposed to PD98059 (for more than 4 weeks) were denoted ACHN (PD) or DU145 (PD) cells, and cells exposed to PD98059 for 4 weeks and then cultured without PD98059 for 2 weeks were denoted ACHN (no PD) or DU145 (no PD) cells, respectively. If not specifically stated, ACHN (pa) cells, ACHN (no PD) cells, DU145 (pa) cells, and DU145 (no PD) cells were cultured without PD98059. ACHN (PD) cells and DU145 (PD) cells were cultured with PD98059 in all assays, except when otherwise specified.
Cell proliferation assay Cells were suspended in either MEM with NEAA or Ham's F-12 medium containing 10% FBS and seeded into 24-well plates at a density of 1  10 Labeling index Labeling index was examined to determine the numbers of cells in S-phase using the bromodeoxyuridine (BrdU) In-Situ detection kit ® (BD Biosciences Pharmingen, San Diego, CA) as described before [11] . In brief, cells were seeded into wells of 48-well-culture plates. On the following day, medium was changed to fresh medium containing 10% FBS with either 0.1% DMSO or 50 M PD98059, and culture was continued. After 16 h, cells were pulse-labeled for 4 h with BrdU. Cells were then fixed, treated with 4 M HCl, and uptaken BrdU was visualized with anti-BrdU antibody.
At least 500 cells were counted for each well, and labeling indices were determined as labeled nuclei/total nuclei ratios and expressed as percentages. Serum-free medium supplemented with HiPerFect reagent and siRNA at the indicated concentrations were mixed, left for 20 min at room temperature, and then added to cells.
Treatment of cells with siRNA
The culture was continued for 2 days. Cells from one set of cultures were counted (three wells of each treatment) and total cell lysates, normalized by cell number, were examined for the expression of ERK proteins by immunoblotting as described below.
Immunoblot analyses Cells grown in 24-well plates were serum-starved overnight and then stimulated or left unstimulated with 10% FBS for the indicated periods. Two sets of culture were prepared, one set was used for immunoblotting and the other set was used for cell counts. Cells were lysed by boiled SDS-sample buffer, and the proteins from 3  10 4 cells in each lysate were separated on SDS-polyacrylamide gels. Proteins were electrotransferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA).
Membranes were incubated with the indicated antibodies, followed by incubation with peroxidase-conjugated secondary antibodies. Proteins were visualized using enhanced chemiluminescence reagents and exposed on X-ray films. X-ray films were scanned and the densities of particular bands were measured by NIH Image ver. 1.64. Fold activation of ERK 2 was estimated by the ratio of optimal density of phospho-ERK 2/ optimal density of ERK 2 in FBS-treated cells to that in untreated cells. ERK 2/vinculin or ERK 1/GAPDH ratios were cauculated as the ratio of optimal density of ERK 2 or 1/optimal density of vinculin or GAPDH.
Statistical analysis Values are presented as mean cell numbers ± SD. Differences between two groups were examined by Mann-Whitney's U test. Differences were considered significant when the P value was less than 0.05.
Results

Effects of chronic exposure to PD98059 on cell proliferation
We first examined whether PD98059 inhibits FBS-induced activation of ERK 1 and 2 in ACHN (pa) cells and DU145 (pa) cells. Proteins from 3  10 4 cells were examined.
As shown in Fig cells and DU145 (PD) cells to PD98059 was decreased, and that the sensitivity was reversed when PD98059 was removed from the culture medium.
Effects of chronic exposure to PD98059 on ERK activation
We next examined the ERK activation by FBS in these cells. ACHN ( The expression and activation of ERK in ACHN (no PD) cells and DU145 (no PD) cells returned to the levels in ACHN (pa) cells and DU145 (pa) cells (Fig. 2 B) , suggesting that elevated expression of ERK caused by chronic exposure to PD98059 was also reversible.
Effects of siRNA for ERK 2 on Erk expression and proliferation
To examine whether upregulation of ERK is responsible for the decrease in sensitivity of ACHN (PD) and DU145 (PD) proliferation to PD98059, we transfected these cells with ERK 2 siRNA. ERK 2 siRNA specifically and efficiently downregulated the expression of ERK 2 in both ACHN (PD) cells and DU145 (PD) cells (Fig. 3 A) . In ACHN (PD) cells treated with 5 nM siRNA and DU145 (PD) cells treated with 10 nM siRNA, expression of ERK 1 protein was elevated. The proliferation of ACHN (PD) cells treated with control siRNA was not significantly inhibited by PD98059-treatment (Fig. 3   B) . On the other hand, the proliferation of ACHN (PD) cells treated with ERK 2 siRNA was significantly and dose-dependently inhibited in response to PD98059-treatment.
Similar results were obtained with DU145 (PD) cells (Fig. 3 C) . These results indicate that upregulation of ERK 2 was responsible for the decrease in sensitivity of their proliferation to PD98059. When ERK 1 was downregulated by siRNA in ACHN (PD) cells and DU145 (PD) cells (Fig. 4 A) , neither the inhibition of their proliferation by PD98059-treatment nor upregulation of ERK 2 was observed ( Fig. 4 and B) .
Discussion
In the present study, we employed two kinds of human tumor cells, originated from renal cell carcinoma and hormone-resistant prostate carcinoma. These tumors are known to be resistant to conventional chemotherapy, radiation therapy, and hormonal therapy.
Therefore, these tumors are good candidates for molecular targeting therapies as well as antiangiogenic therapies. We observed that chronic exposure of these tumor cells to PD98059 decreased the sensitivity of their proliferation to PD98059-treatment. This phenotype was associated with elevated ERK 2 expression, because downregulation of ERK 2 by siRNA restored their sensitivity of proliferation to PD98059 (Fig. 3) . Chronic exposure to another MEK inhibitor, U0126 (at 10 M), also exerted the similar effect on Recently, a CI-1040-resistant clone from colon 26 carcinoma cells has been established and exhibited 100-fold more resistant growth in soft agar to CI-1040 inhibition than the parental cells and 2.8-fold more resistant proliferation in monolayer to CI-1040 inhibition [13] . In this resistant cell line, expression of activated K-Ras was elevated and subsequent upregulation of activated ERK was observed. However, we did not observe the
upregulation of K-Ras in ACHN (PD) cell and DU145 (PD) cells (data not shown).
Finally, downregulation of ERK 2, but not ERK 1, by siRNA restored the sensitivity of proliferation ( Fig. 3 and 4) , suggesting that upregulated ERK 2 was responsible for the decreased sensitivity to PD98059 in ACHN (PD) cell and DU145 (PD) cells and these phenotype was different from the CI-1040-resistant colon 26 cell line. Although treatment with CI-1040 downregulated the activated ERK in both xenograft animal models [6] and clinical trials [8] , the ERK assays used in these studies were normalized by the amount of protein, not by the cell number. Thus, in vivo, upregulation of ERK expression by tumor cells may occur after several weeks of treatment. Indeed, the re-growth of xenografted MDA-MB-231 breast tumors treated with CI-1040 was observed on the 24th day of treatment [14] . Pancreatic BxPc3 xenografts started to grow after the completion of CI-1040-treatment [15] . Furthermore, another MEK inhibitor PD184161 failed to suppress MEK activity in hepatocellular carcinoma xenografts following long term (24 days) and to regress established xenograft tumors [16] . These in vivo studies are consistent with our data ( Fig. 1 B and C) . It is therefore possible that chronic exposure of tumor cells to MEK inhibitors may decrease the sensitivity of their proliferation in vivo as well.
The mechanism underlying upregulation of ERK in ACHN (PD) cells and DU145
(PD) cells is not known. However, downregulation of ERK 2 protein by siRNA significantly restored the sensitivity of proliferation of these cells to PD98059-treatment (Fig. 3 , B and C). In these experiments, the expression of ERK 1 protein was elevated.
However, elevated ERK 1 did not restore the sensitivity of proliferation. Conversely, efficient downregulation of the expression of ERK 1 by siRNA neither affected the proliferation nor upregulation of ERK 2 (Fig. 4 A, B) . In gene-targeted mouse models, ERK 2 -/-mice died in utero, whereas ERK 1 -/-mice were viable, fertile, and grew normally [17, 18] . The proliferation and sustained activation of ERK 2 displayed by embryonic fibroblasts from ERK 1 -/-mice were similar to those of fibroblasts from wild type embryos, suggesting that ERK 2 compensates for ERK 1 deficiency. Taken 
